Épidémiologie de la pemphigoïde bulleuse en Guadeloupe

Cordel, N.; Renier, M.; Samyn, A.; Fauvel, C; Hope-Rapp, Emilie; Gilbert, D.

doi:10.1016/j.annder.2009.10.182

Cited by 7 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Korman hypothesized that the study of Roujeau et al may have a selection bias, favoring the inclusion of severe generalized forms. Korman also hypothesized that ethnic differences could be the cause of higher death rates in France; we did not confirm this latter hypothesis, because most other French studies found much lower death rates …”

Section: Discussionmentioning

confidence: 66%

“…After screening, 77 full-text articles were read, and 56 were included in the analysis (Figure 1). Among the 56 unique articles (12 340 unique patients), individual patient data were available for 16 studies (n = 2122) . Characteristics of included studies, published from 1978 to April 2020, are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…The meta-analysis included 36 studies (Figure 2) performed in Europe (n = 10 132), including 14 in France (n = 1733), 5 in the UK (n = 2922), 3 in Sweden (n = 381), and 1 in Denmark (n = 3281) . A total of 16 studies (n = 1903) were performed in Asia, including Turkey, Iran, Kuwait, Israel, Taiwan, China, Hong Kong, Singapore, Japan, Thailand, and South Korea.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid

et al. 2021

View full text Add to dashboard Cite

The 1-year standardized mortality ratio (SMR) of bullous pemphigoid (BP) has been reported as 2.15 to 7.56 and lower in the US than in Europe.OBJECTIVE To estimate the worldwide 1-year SMR of BP.DATA SOURCES PubMed, Embase, Cochrane Library, Google Scholar, Lissa, and gray literature (eg, medRxiv) were screened for studies of BP published from inception to June 10, 2020, with review of reference lists. STUDY SELECTIONRetrospective and prospective studies reporting 1-year all-cause mortality rate in patients with BP and providing age statistics (eg, mean [SD]).DATA EXTRACTION AND SYNTHESIS Two reviewers independently extracted the data. The 1-year SMR was computed in studies reporting 1-year mortality by combining information on age obtained from studies with aggregate data and individual data. Risk of representativity, misclassification, and attrition bias were assessed by a custom tool. MAIN OUTCOMES AND MEASURESThe primary end point was the worldwide 1-year SMR. Secondary analysis included comparison of 1-year SMRs between continents in a meta-regression.RESULTS Three studies were performed in the US (n = 260), 1 in South America (n = 45), 16 in Asia (n = 1903), and 36 in Europe (n = 10 132) for a total of 56 unique studies and 12 340 unique patients included in the meta-analysis (mean [SD] age, 77.3 [12.7] years; 55.9% women). The mean (SD) patient age in the United States was 75.6 (13.7) years; in Asia, 73.8 (13.6) years; and in Europe, 78.1 (12.3) years. The worldwide 1-year SMR was estimated at 2.93 (95% CI, 2.59-3.28; I 2 = 85.6%) for all 56 studies. The 1-year SMR in the US was 2.40 (95% CI, 0.89-3.90; I 2 = 86.3%) for 3 studies; in Asia, 3.53 (95% CI, 2.85-4.20; I 2 = 86.3%) for 16 studies; and in Europe, 2.77 (95% CI, 2.35-3.19; I 2 = 86.3%) for 36 studies. After adjustment on the expected 1-year mortality rate, the European 1-year SMR did not differ significantly from the 1-year SMR in the United States (−0.48 vs Europe; 95% CI, −2.09 to 1.14; P = .56) and Asia (0.51 vs Europe; 95% CI, −0.56 to 1.58; P = .35). Risk of attrition bias was high (>10% censorship) in 16 studies (28.6%), low in 16 (28.6%), and unclear in 24 (42.9%). Only 4 studies (7.1%) had a sampling method guaranteeing the representativity of BP cases in a population.CONCLUSIONS AND RELEVANCE Although heterogeneity was high and overall quality of follow-up was poor, this meta-analysis confirms the high mortality rate among patients with BP.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Twenty-five of the included studies were published in English, and two were in French. 14,15 The majority of studies included were conducted in Europe (17 studies), seven were conducted in Asia, one in Africa and two in North America (Table 1). Four of the studies determined the incidence only in the adult population, while the remaining 23 studies included people of all ages.…”

Section: Resultsmentioning

confidence: 99%

The global incidence of bullous pemphigoid: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Summary Background Bullous pemphigoid (BP) is an autoimmune blistering disorder that mainly affects older people. Although the disease is associated with considerable morbidity and mortality, the burden of disease worldwide is unclear. Objectives The study aim is to pool the global incidence of BP and determine whether this varies according to geographic area, age group, setting and study quality. Methods Ovid MEDLINE, Ovid Embase and grey literature were systematically searched on 7 April 2020. Two reviewers independently screened, extracted data and appraised each study’s quality using the Joanna Briggs Institute critical appraisal tool. Two domains, indicative of selection and survey bias, were used to identify high‐quality studies. The cumulative incidence was standardized to 1 year and pooled in a random‐effects meta‐analysis. Subgroup and sensitivity analyses were conducted. Results Twenty‐seven studies were identified, of which 23 provided cumulative incidence and four provided incidence rates. The cumulative incidence of BP was 8·2 [95% confidence interval (CI) 4·8–13.7] per million people whereas the incidence rate was 34·2 (95% CI 19·2–60·7) per million person‐years. Of the continents that contributed more than one study, the cumulative incidence was 10·3 (95% CI 5·8–18·2) and 5·6 (95% CI 3·5–9·0) per million people in Europe and Asia, respectively. The incidence was highest in studies including adults only (n = 2), in population‐based studies (n = 9) and in more recent years. The cumulative incidence was higher (13·3 per million people, 95% CI 6·0–29·5) when restricting the analysis to higher‐quality studies (n = 11). High heterogeneity (I2 > 82%) was observed across all pooled estimates. Conclusions The incidence of BP varies globally, is generally low but appears to be increasing over time. The burden of disease is likely to be underestimated.

show abstract

Immunobullous Diseases

Schmidt,

Groves

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

The immunobullous disorders represent a group of conditions characterized by an antibody‐mediated autoimmune response against structural elements of the skin resulting in blistering of the skin and mucosae. Antibody targets include proteins in hemidesmosomes and the basement membrane zone (pemphigoid group), anchoring fibrils in the papillary dermis (epidermolysis bullosa acquisita), desmosomes (pemphigus group) and epidermal transglutaminase (dermatitis herpetiformis). If left untreated, immunobullous disorders may be associated with significant morbidity and mortality so prompt, accurate diagnosis and treatment are mandatory. Therapeutic options include systemic corticosteroid therapy, steroid‐sparing immunosuppressants (e.g. azathioprine and mycophenolates) and immunomodulating agents (e.g. dapsone and tetracyclines). In severe and/or refractory patients, intravenous immunoglobulin, immunoadsorption and the anti‐B‐cell drug rituximab are applied.

show abstract

Épidémiologie de la pemphigoïde bulleuse en Guadeloupe

Cited by 7 publications

References 13 publications

Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid

Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid

The global incidence of bullous pemphigoid: a systematic review and meta‐analysis

Immunobullous Diseases

Contact Info

Product

Resources

About